1. European Centre for Disease Prevention and Control. Novel Coronavirus. Available from: https://www.ecdc.europa.eu/en/novel-coronavirus-china
2. Kementerian Kesehatan Republik Indonesia. Kesiapsiagaan menghadapi Infeksi COVID-19. https://infeksiemerging.kemkes.go.id/situasi-infeksi-emerging/info-corona-virus/situasi-terkini-perkembangan-coronavirus-disease-covid-19-9-maret-2020/#.XmihW6gzbIV
3. European Centre for Disease Prevention and Control. Facts About Novel Coronavirus. Available from https://www.ecdc.europa.eu/en/novel-coronavirus/facts
4. Centers for Disease Control and Prevention. Clinical Care 2019 Novel Coronavirus. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
5. Centers for Disease Control and Prevention. Interim Guidance for Healthcare Professionals 2019 Novel Coronavirus. Available from https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html
6. Banerjee A, Kulcsar K, Misra V, et al. Bats and Coronaviruses. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356540/
7. Perhimpunan Dokter Spesialis Patologi Klinik dan Kedokteran Laboratorium Indonesia. Manajemen Spesimen dan Diagnosis Laboratorium Kasus Suspek 2019-nCoV. Available from: https://www.pdspatklin.or.id/assets/files/pdspatklin_2020_01_26_16_58_51.pdf
8. European Centre for Disease Prevention and Control. Algorithm for management of contacts of probabel or confirmed 2019-nCov cases. Available from: https://www.ecdc.europa.eu/en/publications-data/algorithm-management-contacts-probabel-or-confirmed-2019-ncov-cases
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext
10. WHO. Clinical management of severe acute respiratory infection wen novel coronavirus (nCov) infection is suspected. Available from: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf?sfvrsn=bc7da517_2&download=true
11. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020 Feb 4:1-3.
12. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal. 2005 Dec 1;2(1):69.
13. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends. 2020.
14. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018 May 2;9(2):e00221-18.
15. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications. 2020 Jan 10;11(1):1-4.
16. Centers for Disease Control and Prevention. Infection Control in Healthcare Facilities. Available from: https://www.cdc.gov/sars/guidance/i-infection/healthcare.html